Whole-Genome Sequencing and Genetic Diversity of Human Respiratory Syncytial Virus in Patients with Influenza-like Illness in Sicily (Italy) from 2017 to 2023
Author:
Tramuto Fabio12ORCID, Maida Carmelo Massimo12ORCID, Randazzo Giulia2ORCID, Guzzetta Valeria2ORCID, Santino Arianna2ORCID, Li Muli Rita2, Costantino Claudio12ORCID, Graziano Giorgio2ORCID, Amodio Emanuele1ORCID, Mazzucco Walter12ORCID, Vitale Francesco12
Affiliation:
1. Department of Health Promotion Sciences Maternal and Infant Care, Internal Medicine and Medical Specialties “G. D’Alessandro”—Hygiene Section, University of Palermo, 90133 Palermo, Italy 2. Regional Reference Laboratory for Molecular Surveillance of Influenza, Clinical Epidemiology Unit, University Hospital “Paolo Giaccone”, 90133 Palermo, Italy
Abstract
Monitoring the genetic variability of human respiratory syncytial virus (hRSV) is of paramount importance, especially for the potential implication of key antigenic mutations on the emergence of immune escape variants. Thus, to describe the genetic diversity and evolutionary dynamics of hRSV circulating in Sicily (Italy), a total of 153 hRSV whole-genome sequences collected from 770 hRSV-positive subjects between 2017 and 2023, before the introduction of expanded immunization programs into the population, were investigated. The phylogenetic analyses indicated that the genotypes GA.2.3.5 (ON1) for hRSV-A and GB.5.0.5a (BA9) for hRSV-B co-circulated in our region. Amino acid (AA) substitutions in the surface and internal proteins were evaluated, including the F protein antigenic sites, as the major targets of immunoprophylactic monoclonal antibodies and vaccines. Overall, the proportion of AA changes ranged between 1.5% and 22.6% among hRSV-A, whereas hRSV-B varied in the range 0.8–16.9%; the latter was more polymorphic than hRSV-A within the key antigenic sites. No AA substitutions were found at site III of both subgroups. Although several non-synonymous mutations were found, none of the polymorphisms known to potentially affect the efficacy of current preventive measures were documented. These findings provide new insights into the global hRSV molecular epidemiology and highlight the importance of defining a baseline genomic picture to monitor for future changes that might be induced by the selective pressures of immunological preventive measures, which will soon become widely available.
Funder
Merck Sharp & Dohme Corp
Reference80 articles.
1. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: A systematic analysis;Li;Lancet,2022 2. Díez-Gandía, E., Gómez-Álvarez, C., López-Lacort, M., Muñoz-Quiles, C., Úbeda-Sansano, I., Díez-Domingo, J., Orrico-Sánchez, A., and Study Collaborators (2021). The impact of childhood RSV infection on children’s and parents’ quality of life: A prospective multicenter study in Spain. BMC Infect. Dis., 21. 3. Tramuto, F., Maida, C.M., Di Naro, D., Randazzo, G., Vitale, F., Restivo, V., Costantino, C., Amodio, E., Casuccio, A., and Graziano, G. (2021). Respiratory Syncytial Virus: New Challenges for Molecular Epidemiology Surveillance and Vaccination Strategy in Patients with ILI/SARI. Vaccines, 9. 4. Epidemiological Study of Respiratory Virus Infections among Hospitalized Children Aged 14 Years and Younger during COVID-19 Pandemic in Wuhan, China, 2018–2022;Hao;J. Glob. Infect. Dis.,2023 5. Burden of respiratory syncytial virus infection in older and high-risk adults: A systematic review and meta-analysis of the evidence from developed countries;Martin;Eur. Respir. Rev.,2022
|
|